title: [Prognosis and prognostic factor analysis epithelial ovarian cancer].
abstract: OBJECTIVE
  To investigate the prognosis change and prognostic factors of advanced epithelial ovarian cancer in recent over twenty years.
  
  
  METHODS
  One hundred and fourty patients with advanced epithelial ovarian cancer were analyzed. They were divided into two groups based on their operation time. 56 patients operated before Jan. 1980 were included in the first group, and the other 84 patients in the second group. Kaplan-Meier survival curves of the two groups were calculated, and Cox model was used to evaluate the prognostic factors of the disease at univariate and multivariate levels using SPSS and SURVCALC software.
  
  
  RESULTS
  There was no pathological difference in between the two groups, but the patients in the second group received more aggressive chemotherapy. The overall 1-, 2-, and 5-year survival rates were 61.2%, 32.1%, and 8.5%, respectively. In the first group they were 42.3%, 29.6% and 4.5% respectively and in the second group 69.3%, 36.2%, and 11.2% respectively. The prognosis of the patients in the second group was better than that in the first group, P < 0.05. Univariate analysis revealed that stage, grade, residual tumor size and chemotherapy were significant predictors of patients' outcome. COX regression analysis identified that they were all independent prognostic factors. The patients with advanced, low grade, residual tumor (> 2 cm) had poor prognosis. The prognosis of the patients who received equal or more than four, especially six cycles combined chemotherapy was improved.
  
  
  CONCLUSIONS
  The prognosis of the patients with advanced ovarian cancer has improved in recent over 10 years, higher optimal cytoreductive rate and equal or more than six cycles combined chemotherapy are important measures for the better prognosis of advanced ovarian cancer.
authors.affiliation: First School of Clinical Medicine, Beijing Medical University.
authors.forename: H
authors.initials: H
authors.lastname: Wen
authors.forename: W
authors.initials: W
authors.lastname: Sun
authors.forename: Y
authors.initials: Y
authors.lastname: Guo
mesh_terms: D002288:Adenocarcinoma, Mucinous / Q000175:diagnosis / Q000628:therapy; D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D018269:Carcinoma, Endometrioid / Q000175:diagnosis / Q000628:therapy; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D018284:Cystadenocarcinoma, Serous / Q000175:diagnosis* / Q000628:therapy; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000175:diagnosis* / Q000628:therapy; D011379:Prognosis
chemical_list: D003520:Cyclophosphamide; D002945:Cisplatin